Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea · Delayed Price · Currency is KRW

2,275.00

+135.00 (6.31%)

At close: Oct 1, 2026

Market Cap	201.28B +45.2%
Revenue (ttm)	3.03B -76.2%
Net Income	-11.57B
EPS	-130.78
Shares Out	94.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	601,718
Open	2,200.00
Previous Close	2,140.00
Day's Range	2,160.00 - 2,325.00
52-Week Range	1,372.00 - 4,690.00
Beta	0.42
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2010

Employees 100

Stock Exchange KOSDAQ

Ticker Symbol 217730

Full Company Profile

Financial Performance

In 2025, Kangstem Biotech's revenue was 3.57 billion, a decrease of -53.88% compared to the previous year's 7.75 billion. Losses were -10.48 billion, 36.7% more than in 2024.

Financial Statements